Stock Track | Collegium Pharmaceutical Soars 11.58% Pre-market on Strong Q3 Results and Raised 2025 Guidance

Stock Track11-06

Shares of Collegium Pharmaceutical (COLL) are surging 11.58% in pre-market trading on Thursday following the company's impressive third-quarter financial results and increased full-year guidance. The pharmaceutical firm, specializing in pain management and central nervous system disorders, reported better-than-expected earnings and revenue for Q3 2025.

Collegium Pharmaceutical announced adjusted earnings per share of $2.25, surpassing the IBES estimate of $2.05. The company's Q3 revenue reached $209.4 million, significantly exceeding analysts' expectations of $191.2 million. This represents a robust 31% year-over-year increase in net revenue, driven by strong performance across its product portfolio.

The company's pain portfolio showed particular strength, with net revenue climbing 11% compared to the same period last year. Additionally, Collegium raised its full-year 2025 guidance, now expecting net revenue in the range of $775 to $785 million and adjusted EBITDA between $460 and $470 million. This upward revision in outlook, coupled with the strong quarterly performance, has likely fueled investor optimism and contributed to the stock's pre-market surge.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1168044561?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-06 20:38","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1168044561","market":"sg","top_or_hot":-1,"title":"Stock Track | Collegium Pharmaceutical Soars 11.58% Pre-market on Strong Q3 Results and Raised 2025 Guidance","media":"Stock Track","content":"<p>Shares of Collegium Pharmaceutical (COLL) are surging 11.58% in pre-market trading on Thursday following the company's impressive third-quarter financial results and increased full-year guidance. The pharmaceutical firm, specializing in pain management and central nervous system disorders, reported better-than-expected earnings and revenue for Q3 2025.</p>\n\n<p>Collegium Pharmaceutical announced adjusted earnings per share of $2.25, surpassing the IBES estimate of $2.05. The company's Q3 revenue reached $209.4 million, significantly exceeding analysts' expectations of $191.2 million. This represents a robust 31% year-over-year increase in net revenue, driven by strong performance across its product portfolio.</p>\n\n<p>The company's pain portfolio showed particular strength, with net revenue climbing 11% compared to the same period last year. Additionally, Collegium raised its full-year 2025 guidance, now expecting net revenue in the range of $775 to $785 million and adjusted EBITDA between $460 and $470 million. This upward revision in outlook, coupled with the strong quarterly performance, has likely fueled investor optimism and contributed to the stock's pre-market surge.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Collegium Pharmaceutical Soars 11.58% Pre-market on Strong Q3 Results and Raised 2025 Guidance</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Collegium Pharmaceutical Soars 11.58% Pre-market on Strong Q3 Results and Raised 2025 Guidance\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-11-06 20:38</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shares of Collegium Pharmaceutical (COLL) are surging 11.58% in pre-market trading on Thursday following the company's impressive third-quarter financial results and increased full-year guidance. The pharmaceutical firm, specializing in pain management and central nervous system disorders, reported better-than-expected earnings and revenue for Q3 2025.</p>\n\n<p>Collegium Pharmaceutical announced adjusted earnings per share of $2.25, surpassing the IBES estimate of $2.05. The company's Q3 revenue reached $209.4 million, significantly exceeding analysts' expectations of $191.2 million. This represents a robust 31% year-over-year increase in net revenue, driven by strong performance across its product portfolio.</p>\n\n<p>The company's pain portfolio showed particular strength, with net revenue climbing 11% compared to the same period last year. Additionally, Collegium raised its full-year 2025 guidance, now expecting net revenue in the range of $775 to $785 million and adjusted EBITDA between $460 and $470 million. This upward revision in outlook, coupled with the strong quarterly performance, has likely fueled investor optimism and contributed to the stock's pre-market surge.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"COLL","symbol_name":"Collegium Pharmaceutical, Inc.","start_time":0,"source_url":"","article_id":"1168044561","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1168044561","pubTimestamp":1762432703,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Shares of Collegium Pharmaceutical (COLL) are surging 11.58% in pre-market trading on Thursday following the company's impressive third-quarter financial results and increased full-year guidance. The...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"COLL":"Collegium Pharmaceutical, Inc."},"translate_title":"个股赛道|Collegium Pharmaceutical盘前大涨11.58%Q3业绩强劲上调2025年指引","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"COLL":1},"content_text":"Shares of Collegium Pharmaceutical (COLL) are surging 11.58% in pre-market trading on Thursday following the company's impressive third-quarter financial results and increased full-year guidance. The pharmaceutical firm, specializing in pain management and central nervous system disorders, reported better-than-expected earnings and revenue for Q3 2025.\nCollegium Pharmaceutical announced adjusted earnings per share of $2.25, surpassing the IBES estimate of $2.05. The company's Q3 revenue reached $209.4 million, significantly exceeding analysts' expectations of $191.2 million. This represents a robust 31% year-over-year increase in net revenue, driven by strong performance across its product portfolio.\nThe company's pain portfolio showed particular strength, with net revenue climbing 11% compared to the same period last year. Additionally, Collegium raised its full-year 2025 guidance, now expecting net revenue in the range of $775 to $785 million and adjusted EBITDA between $460 and $470 million. This upward revision in outlook, coupled with the strong quarterly performance, has likely fueled investor optimism and contributed to the stock's pre-market surge.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1168044561","isCrawlerRequest":true}